Valuation: Rezolute, Inc.

Market Cap 487M 418M 390M 358M 673M 46.53B 684M 4.6B 1.8B 23.34B 1.83B 1.79B 77.16B P/E 2026 *
-6.74x
P/E 2027 * -7.26x
Enterprise Value 487M 418M 390M 358M 673M 46.53B 684M 4.6B 1.8B 23.34B 1.83B 1.79B 77.16B EV / Sales 2026 *
-
EV / Sales 2027 * 211x
Free-Float
89.85%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Rezolute, Inc.

1 day+1.29%
1 week+0.43%
1 month+6.07%
3 months+52.26%
6 months+43.90%
Current year+100.00%
1 week 4.44
Extreme 4.44
4.88
1 month 4.4
Extreme 4.395
5.4
Current year 1.87
Extreme 1.87
5.42
1 year 1.07
Extreme 1.07
11.46
3 years 0.72
Extreme 0.72
11.46
5 years 0.72
Extreme 0.72
11.46
10 years 0.72
Extreme 0.72
100
Manager TitleAgeSince
Chief Executive Officer 58 30/01/2013
Director of Finance/CFO 52 23/01/2024
Chief Operating Officer - -
Director TitleAgeSince
Chairman 58 04/05/2022
Director/Board Member 55 20/11/2019
Chairman 68 10/02/2019
Date Insider Type Main position Quantity % Market Cap.
7/2/26 A Tax

Chief Technology Officer

-3,062 0.0035%
7/2/26 A Tax

Chief Financial Officer

-3,062 0.0035%
7/2/26 A Tax

Chief Executive Officer

-8,004 0.0092%
Change 5-day change 1-year change 3-year change Capi.($)
+1.29%+0.43%-27.05%+221.09% 487M
-1.90%+2.37%+69.11%+110.88% 73.45B
+0.87%+17.17%+53.05%+95.59% 62.99B
+1.71%-1.22%+2.71%+493.91% 28.05B
-1.40%+4.18%+54.52%+19.60% 25.42B
+21.96%+21.98%+1.54%-3.75% 23.3B
+2.28%+7.98%+42.75%-12.34% 19.45B
0.00%-4.11%+243.99%+423.83% 18.16B
-3.50%-0.95%+17.17%+534.55% 16.53B
+2.39%+7.96%+44.96%+154.52% 13.16B
Average +2.46%+2.55%+50.28%+203.79% 28.1B
Weighted average by Cap. +1.70%+4.38%+57.09%+166.79%

Financials

2026 *2027 *
Net sales - 2.3M 1.98M 1.85M 1.69M 3.18M 220M 3.24M 21.78M 8.53M 110M 8.65M 8.46M 365M
Net income -72.7M -62.36M -58.23M -53.42M -100M -6.95B -102M -687M -269M -3.48B -273M -267M -11.52B -75.12M -64.44M -60.17M -55.2M -104M -7.18B -106M -710M -278M -3.6B -282M -276M -11.91B
Net Debt - -
Logo Rezolute, Inc.
Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.
Employees
68
Date Price Change Volume
19/08/26 $4.720 +1.29% 1,220,171
18/08/26 $4.660 -0.43% 912,778
17/08/26 $4.680 +1.74% 535,242
14/08/26 $4.600 0.00% 657,137
13/08/26 $4.600 -2.13% 800,613
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
4.660USD
Average target price
7.667USD
Spread / Average Target
+64.52%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RZLT Stock